Abstract
Antibody therapy has demonstrated great potential for treating central nervous system (CNS) disorders. Since therapeutic efficacy relies on sufficient exposure in specific brain regions, quantitative understanding of antibody distribution within the brain is crucial. Additionally, insights into antibody brain distribution help elucidate how pathological antibodies accumulate during encephalitis. Accordingly, this study investigated the regional distribution of a non-target-binding antibody (trastuzumab) and a brain-target-binding antibody (anti-NMDAR1) following systemic and intra-CNS administration in rats. After systemic administration, both antibodies showed similar distribution across brain regions, with the olfactory bulb exhibiting significantly higher concentrations. Other regions had comparable exposure, with the striatum or hippocampus showing the lowest exposure. Intra-CSF administration resulted in similar distribution patterns but achieved significantly higher concentrations than systemic administration. In contrast, intra-striatal administration led to diverse distribution, with the highest concentrations near the injection site. Calculations based on striatum and interstitial fluid (ISF) concentrations indicated antibody accumulation in the perivascular space after intra-CNS administration. Target binding influenced distribution primarily after intra-CSF administration, where anti-NMDAR1 showed lower ISF concentrations early and reduced CSF concentrations later. These findings provide valuable quantitative insights for optimizing brain-targeted antibody therapies and understanding pathological antibody distribution in CNS disorders.
Get full access to this article
View all access options for this article.
References
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
